These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33077903)

  • 1. Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres.
    McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A
    Bone Marrow Transplant; 2021 Mar; 56(3):738-740. PubMed ID: 33077903
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
    Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
    Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
    Chan H; Chai K; Shih S; Lewsey R; Chen K; McDiarmid B; Jackson S; Simpson D
    Br J Haematol; 2019 Nov; 187(4):470-477. PubMed ID: 31298750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
    Swan D; Henderson R; McEllistrim C; Naicker SD; Quinn J; Cahill MR; Mykytiv V; Lenihan E; Mulvaney E; Nolan M; Parker I; Natoni A; Lynch K; Ryan AE; Szegezdi E; Krawczyk J; Murphy P; O'Dwyer M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):847-852. PubMed ID: 35985959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chalazion in a patient with multiple myeloma treated with bortezomib.
    Ghimire B; Hamajima Y; Carbajal-Carballo L; Anusim N
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma].
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Rinsho Ketsueki; 2015 Aug; 56(8):1069-75. PubMed ID: 26345569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
    Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
    Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
    Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.
    O'Dwyer M; Henderson R; Naicker SD; Cahill MR; Murphy P; Mykytiv V; Quinn J; McEllistrim C; Krawczyk J; Walsh J; Lenihan E; Kenny T; Hernando A; Hirakata G; Parker I; Kinsella E; Gannon G; Natoni A; Lynch K; Ryan AE
    Blood Adv; 2019 Jun; 3(12):1815-1825. PubMed ID: 31201169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, bortezomib and dexamethasone (CyBorD): a promising regimen for renal light chain deposit disease.
    Dutta A; Kesari K; Singh T
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31948981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
    Jimenez-Zepeda VH; Duggan P; Neri P; Tay J; Bahlis NJ
    Ann Hematol; 2017 Mar; 96(3):431-439. PubMed ID: 28074255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
    He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
    Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
    Ong SY; Ng HY; Surendran S; Linn YC; Chen Y; Goh YT; Diong C; Gopalakrishnan SK
    Br J Haematol; 2015 Jun; 169(5):754-6. PubMed ID: 25413901
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient.
    Yang D; Agrawal N; Marcus C; Roy N; Richards KR; Nahas MR; Cardarelli F
    Am J Ther; 2021 Jul-Aug 01; 28(4):e488-e491. PubMed ID: 34228654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
    Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
    Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CyBorD induction therapy in clinical practice.
    Areethamsirikul N; Masih-Khan E; Chu CM; Jimenez-Zepeda V; Reece DE; Trudel S; Kukreti V; Tiedemann R; Chen C
    Bone Marrow Transplant; 2015 Mar; 50(3):375-9. PubMed ID: 25599165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.